Form 4: NewGenIvf Group Executive Reports Stock Transaction
Insider Transaction (Form 4)
Hei Yue Tina Fong, Chief Marketing Officer and a Director of NewGenIvf Group Ltd, reported multiple transactions in common stock on October 5, 2026.
Summary
- Option exercise/conversion: acquired 139,811 Class B Ordinary Shares at $0.00 ($14) on October 5, 2026; holds 146,133 after (Direct).
- Option exercise/conversion: disposed of 49,078 Stock Options (Right to Buy) on October 5, 2026 (Direct).
- Option exercise/conversion: disposed of 90,713 Stock Options (Right to Buy) on October 5, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Hei Yue Tina Fong — Director, Officer (Chief Marketing Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-05 | Option exercise/conversion | Class B Ordinary Shares | 139,811 | $0 | $14 | 146,133 |
| 2026-10-05 | Option exercise/conversion | Stock Options (Right to Buy) | 49,078 | — | — | 0 |
| 2026-10-05 | Option exercise/conversion | Stock Options (Right to Buy) | 90,713 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-05 | Option exercise/conversion (139,811 shares) |
| 2026-10-05 | Option exercise/conversion (49,078 shares) |
| 2026-10-05 | Option exercise/conversion (90,713 shares) |
Keywords
insider transaction, Form 4, NIVF, NewGenIvf Group Ltd, neutral, Hei Yue Tina Fong
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.